Why the study?
Heart failure patients face increased vulnerability to respiratory infections, but despite recognized benefits, pneumococcal and influenza vaccination coverage remains below expectations.
What is the coverage of influenza and pneumococcal vaccination in patients with heart failure, and does it improve survival and reduce hospitalizations?
What is the coverage of influenza and pneumococcal vaccination in patients with heart failure, and does it improve survival and reduce hospitalizations?
Vaccination coverage for influenza and pneumococcus varies widely among heart failure patients, despite evidence of beneficial effects on survival and hospitalizations.
Variable HF vaccination rates signal care gaps; leaves open need for targeted uptake strategies to curb infection risks.
Background/Objectives: As heart failure (HF) patients face increased vulnerability to respiratory infections, optimizing pneumococcal and influenza vaccination coverage becomes pivotal for mitigating additional health risks and reducing hospitalizations, morbidity, and mortality rates within this population. In this specific subpopulation of patients, vaccination coverage for pneumococcal and influenza holds heightened significance compared to other vaccines due to their susceptibility to respiratory infections, which can exacerbate existing cardiovascular conditions and lead to severe complications or even death. However, despite the recognized benefits, vaccination coverage among HF patients remains below expectations. The aim of the present systematic review was to assess the vaccination coverage for influenza and pneumococcus in HF patients from 2005 to 2023 and the vaccination’s effects on survival and hospitalizations. Methods: The authors developed the protocol of the review in accordance with the PRISMA guidelines, and the search was performed in databases including PubMed and Scopus. After the initial search, 851 studies were found in PubMed Library and 1961 in Scopus (total of 2812 studies). Results: After the initial evaluation, 23 publications were finally included in the analysis. The total study population consisted of 6,093,497 participants. Regarding the influenza vaccine, vaccination coverage ranged from low rates of 2.5% to very high rates of 97%, while the respective pneumococcal vaccination coverage ranged from 20% to 84.6%. Most studies demonstrated a beneficial effect of vaccination on survival and hospitalizations. Conclusions: The present systematic review study showed a wide variety of vaccination coverage among patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Papagiannis et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: